Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atozycel
- Development stage
- Unknown
- Lead developer
- Pharm-Sintez
- Modality
- Small Molecules
- Administration
- Subcutaneous, Intravenous
01
Overview
Atozycel is a generic formulation of azacitidine, a pyrimidine nucleoside analog that functions as a hypomethylating agent. Developed and marketed by the Russian pharmaceutical company Pharm-Sintez, it is indicated for the treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Azacitidine acts by incorporating into DNA and RNA. In DNA, it acts as a potent inhibitor of DNA methyltransferases (DNMTs), leading to DNA hypomethylation. This process can reactivate tumor suppressor genes that were silenced by hypermethylation, promoting cell differentiation and apoptosis. Additionally, azacitidine exerts direct cytotoxic effects on abnormal hematopoietic cells in the bone marrow by disrupting protein synthesis through its incorporation into RNA.
- Brand names
- Atozycel
- Other names
- Атозицел
02
Targets
DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on Atozycel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Atozycel.